TCI Wealth Advisors’s Maravai LifeSciences MRVI Stock Holding History

TCI Wealth Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1	Closed	-$15	–	1439
2023 Q1	$15	Buy	+1	New	+$14	﹤0.01%	2499
2022 Q4	–	Sell	-1	Closed	–	–	2599
2022 Q3	$0	Buy	+1	New	+$25	﹤0.01%	2469

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

TCI Wealth Advisors's MRVI Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Maravai LifeSciences (MRVI) in Q2 2023, closing a stake of 1 share — an estimated $15 sold.

TCI Wealth Advisors first reported a position in MRVI in Q3 2022 and held it in 2 quarters. The position peaked at $15 in Q1 2023. 221 funds tracked by Wall St. Rank hold MRVI as of Q2 2023.

TCI Wealth Advisors reported no remaining Maravai LifeSciences position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 1 Maravai LifeSciences share in Q2 2023, an estimated $15.
TCI Wealth Advisors first reported a position in Maravai LifeSciences in Q3 2022 and held it in 2 quarters.
TCI Wealth Advisors's Maravai LifeSciences position peaked at $15 in Q1 2023.
221 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.